What are the most common respiratory illnesses in India and how are they managed?

Common Respiratory Illnesses in India

In India, obstructive airway diseases (COPD and asthma) are the most prevalent respiratory conditions, accounting for approximately 43% of cases presenting to pulmonary clinics, followed by infectious lung diseases including tuberculosis (15%), and acute respiratory infections which remain a leading cause of childhood mortality. 1

Major Respiratory Disease Categories

Obstructive Airway Diseases (Most Common)

• COPD and asthma combined represent 43% of respiratory presentations in referral pulmonary clinics 1
• These conditions are increasingly prevalent due to rapid urbanization and household air pollution exposure 2, 3
• Household air pollution from solid cooking fuels significantly increases risk of COPD development, with odds ratios consistently exceeding 1.0 in exposed individuals 3

Infectious Respiratory Diseases

Tuberculosis remains a critical public health concern:

• TB accounts for approximately 15% of infectious lung disease presentations 1
• In high-prevalence areas, chronic cough should be defined as 2-3 weeks duration (not the typical 8 weeks used elsewhere) to enable earlier TB detection 4
• One-third of the global TB-infected population resides in regions including India 4

Acute Respiratory Infections (ARI) in Children:

• ARI/pneumonia causes approximately one-fourth of all deaths in children under 5 years in India 5
• Common bacterial pathogens include Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Gram-negative bacilli 5
• Respiratory syncytial virus (RSV) is the predominant viral pathogen 5
• In-vitro resistance to cotrimoxazole is high 5

Viral Respiratory Infections:

• Influenza viruses, RSV, rhinovirus, parainfluenza, and adenovirus circulate throughout India 6
• Human metapneumovirus (HMPV) shows 3.2-3.3% positivity rates in tested patients, with highest rates (4.5-4.6%) in children aged 1-2 years 7

Other Significant Conditions

• Bronchogenic carcinoma: 8% of presentations 1
• Interstitial lung diseases (ILD): 4%, with sarcoidosis (37.3%) being most common, followed by connective tissue disease-related ILD (19.3%), idiopathic pulmonary fibrosis (17%), and hypersensitivity pneumonitis (14.4%) 1, 8
• Pleural diseases: 4.6% 1
• Chronic cough of undiagnosed etiology: 6.5% 1

Management Approaches

Community-Acquired Pneumonia

For hospitalized non-severe pneumonia (CURB-65 score 0-2):

• First-line: Co-amoxiclav 625 mg three times daily orally or doxycycline 200 mg loading then 100 mg daily 9, 10
• Alternative: Macrolide (clarithromycin 500 mg twice daily or azithromycin) or fluoroquinolone with enhanced pneumococcal activity (levofloxacin 500 mg daily or moxifloxacin 400 mg daily) 9, 10
• Treatment duration: 7-10 days for uncomplicated cases 10

For severe pneumonia (CURB-65 score 3-5):

• Co-amoxiclav 1.2 g IV three times daily or cefuroxime 1.5 g IV three times daily or cefotaxime 1 g IV three times daily 9, 10
• Plus macrolide (erythromycin 500 mg IV four times daily or clarithromycin 500 mg IV twice daily) 9, 10
• Alternative: Fluoroquinolone (levofloxacin 500 mg twice daily IV) plus either macrolide or beta-lactam 10

COPD Exacerbations

Antibiotics are indicated when exacerbation includes:

• Increased sputum purulence AND increased sputum volume AND increased dyspnea 10
• All severe COPD exacerbations requiring hospitalization 9

Antibiotic choices:

• Co-amoxiclav 625 mg three times daily orally or doxycycline 200 mg loading then 100 mg daily 9
• Cover S. pneumoniae, H. influenzae, and M. catarrhalis 9
• Duration: Minimum 7 days (except clarithromycin/azithromycin which have shorter courses) 10

Childhood ARI/Pneumonia

Case management follows WHO guidelines modified by IndiaCLEN (2010):

• Oxygen therapy is critical for severe/very severe pneumonia to maintain SaO2 ≥92% 11
• Measles vaccination for all infants 5
• Zinc supplementation may prevent pneumonia but has no therapeutic benefit once infected 5
• Vitamin A shows insufficient evidence for protection or cure 5

Tuberculosis Screening

In high-prevalence areas:

• Evaluate all patients with cough lasting ≥2-3 weeks (not 8 weeks) 4
• Obtain sputum for Gram stain, culture, and acid-fast bacilli 4
• Chest radiography for suspected cases 4
• Treatment duration: 21 days when Legionella pneumophila suspected 10

Critical Monitoring Parameters

For hospitalized patients, monitor twice daily minimum:

• Temperature, respiratory rate, pulse, blood pressure, mental status, oxygen saturation, and inspired oxygen concentration 11
• Fever should resolve within 2-3 days of appropriate antibiotic therapy 10

Discharge criteria - patients should NOT have ≥2 of:

• Temperature >37.8°C, heart rate >100/min, respiratory rate >24/min, systolic BP <90 mmHg, oxygen saturation <90%, inability to maintain oral intake, or abnormal mental status 11

Key Pitfalls to Avoid

• Do not routinely prescribe antibiotics for acute bronchitis in previously well adults without pneumonia 9
• Do not use common cold as indication for antibiotics - symptoms can last up to 2 weeks and antibiotics increase adverse effects without benefit 12
• Be aware that in-vitro cotrimoxazole resistance is high in India, limiting its utility 5
• Consider local antimicrobial resistance patterns, particularly for S. aureus and MRSA 9